EPS for Minerva Neurosciences, Inc. (NERV) Expected At $-0.30

April 21, 2018 - By Louis Casey

Minerva Neurosciences, Inc. (NASDAQ:NERV) Logo

Analysts expect Minerva Neurosciences, Inc. (NASDAQ:NERV) to report $-0.30 EPS on May, 3.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.3 EPS. After having $-0.24 EPS previously, Minerva Neurosciences, Inc.’s analysts see 25.00 % EPS growth. The stock increased 0.70% or $0.05 during the last trading session, reaching $7.2. About 92,248 shares traded. Minerva Neurosciences, Inc. (NASDAQ:NERV) has declined 28.40% since April 21, 2017 and is downtrending. It has underperformed by 39.95% the S&P500.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company has market cap of $279.00 million. The company's lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that completed Phase IIb clinical trial. It currently has negative earnings. It also offers MIN-202, which completed Phase IIa clinical trial for treating primary insomnia, as well as completed Phase 1b used for the treatment of major depressive disorder; and MIN-117, a compound that completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.